Global Advances in Breast Cancer Detection Creating USD 5.13 Billion Opportunity
G
lobally, breast cancer effects 2.1 million women every year. In 2018 alone, it was the cause of nearly 627,000 deaths, according to the World Health Organization, accounting for 15pc of all cancer deaths among women.
WHO also noted that while breast cancer rates are found in more developed regions, it's also increased in nearly every region globally. Developing nations have lower survival rates because of a great lack in early detection programs which results in a high proportion of women presenting late stages of cancer, they note.
It's why WHO also recommends early detection, calling it critical in an effort to detect cancer early enough where it can be treated and potentially cured. As companies race to help women, it's creating a breast imaging market worth up to $5.13 billion over the next four years, according to Meticulous Research.
Some of the top companies leading the charge include Izotropic Corporation (CSEIZO)(OTCPKIZOZF), ENDRA Life Sciences Inc. (NASDAQNDRA), Boston Scientific Corporation (NYSEBSX), Seattle Genetics Inc. (NASDAQSGEN), and Puma Biotechnology Inc. (NASDAQPBYI).
Izotropic Corporation (CSEIZO) (OTCPKIZOZF) BREAKING NEWS Izotropic Corporation provided an update regarding early stage commercialization action plans to bring its globally licensed breast CT technology to market. The first initiative underway includes collaborative design and engineering of the commercial model and preparation for manufacturing and submission for FDA approval and European CE Mark. The second is a near-term initiative that includes proposals and presentations to early-adopter hospitals and medical organizations who have expressed interest in the Company's breast CT technology. The primary objective is to begin securing important collaborative relationships with major customers, to obtain product orders, support FDA procedural requirements, and to establish framework and in-hospital practices for the integration and day to day use of breast CT. The Company believes securing early collaborations with well-known hospital and medical organizations will set the stage for rapid adoption of breast CT and further validate the Company's technology.
Other updates include recent additional listings on the Berlin, Tradegate, and Stuttgart Stock Exchanges and along with the listing in Frankfurt are under the symbol '1R3' (WKN A2JNLV). The Company's shares continue to be listed on the Canadian Securities Exchange under the symbol 'IZO' and on the OTC Markets under the symbol 'IZOZF'. The Company also advises that DTC has activated the Fast Automated Securities Transfer Program (FAST), which eliminates the movement of physical securities by allowing agents to act as custodians for DTC. DTC participants shall now see the security as a FAST security. This is an exciting time for the Company as it moves into the commercialization phase after years of breast CT technology research and development at UC Davis Medical Center. The Company is pleased to further expand access to Izotropic shares with the DTC FAST accreditation as well as listing its securities on additional European stock exchanges to broaden its exposure to investors and generate awareness for its technology and mandates. It is critical that the Company continues to increase its activities and engagement with both European investors and Scientific communities in Europe, as Belgium, Luxembourg, the Netherlands, and France have the highest rates of breast cancer in the world according to the World Cancer Research Fund.
✔️ Global Advances in Breast Cancer Detection Creating USD 5.13 Billion Opportunity
💕 Found this article helpful? Spread the word and support us!